Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education.
Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.
In this podcast episode, listen to breast cancer experts Thomas Bachelot, MD, PhD; Adam M. Brufsky, MD, PhD; and Cristina Saura, MD, PhD, discuss clinical considerations for patients with HER2-positive MBC, with topics including:
Content based on an online CME program supported by an educational grant from Daiichi Sankyo, Inc.
Link to full program, including associated downloadable slidesets: https://www.clinicaloptions.com/oncology/programs/esmo-breast-sat
Podcast featuring international and US experts discussing early HR+/HER2- breast cancer management including leveraging CDK4/6 inhibitors, from Clinical Care Options (CCO)
On-demand webcast from a live Clinical Care Options (CCO) webinar with global expert perspectives on CDK4/6 inhibitors for early-stage HR+/HER2- breast cancer
From Clinical Care Options (CCO), video of pharmacist discussion of recently approved agents targeting HER2 and TROP2 for metastatic cancers
Gain key clinical insights quickly with this short slideset from CCO on the latest data on treatment for patients with HR+/HER2- early breast cancer